Comparative Pharmacokinetics of Cholecalciferol in Dogs from 2 Different Oral Formulations Using Corrective Measures to Overcome Interference from Endogenous Cholecalciferol

Abstract

The aim of the preclinical investigation was to obtain single dose pharmacokinetics in dogs from 2 different oral cholecalciferol formulations using corrective measures to overcome the interference of endogenous cholecalciferol. 6 dogs were fasted overnight and the following day received 60 000 IU dose cholecalciferol [reference, Eris^®, vs. test, Sunbless^®] by oral dosing. Blood samples were collected on day 0 (baseline establishment) and after dosing on day 1 up to 28 days. The serum samples were extracted using protein precipitation/solid phase extraction and analysed to determine cholecalciferol by LC-MS/MS assay with calibrators prepared from cholecalciferol free serum. Standard pharmacokinetic analysis was carried out to assess pharmacokinetic parameters. An un-paired t-test was employed for comparing statistical significance between formulations. Serum cholecalciferol concentration vs. time profiles for the 2 formulations was almost superimposable. None of the pharmacokinetic parameters showed statistically significant differences (p>0.05) between the 2 treatments. For example: C_max (ng/mL) and AUC_inf (ng.h/mL) derived after the baseline corrections were 708.65 and 38 877.18 for reference and 743.71 and 40 665.51 for test, respectively. Pharmacokinetics of cholecalciferol was comparable between reference vs. test formulations. The procedures, baseline correction and employment of cholecalciferol devoid serum, can be readily adopted in future pharmacokinetic studies in animals or humans.

Key words

vitamin D3 - LC-MS/MS - solid phase extraction - pharmacokinetic - serum

• References

• 1 Holick MF. Vitamin D, status: measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19: 73-78
• 2 Mittal H, Rai S, Shah D. et al. 300,000 IU or 600,000 IU of oral vitamin D3 for treatment of nutritional rickets: a randomized controlled trial. Indian Pediatr 2014; 51: 265-272
• 3 Fernandes AS, Lobo S, Sandes AR. et al. Vitamin D-dependent rickets: a resurgence of the rachitic lung in the 21st century. BMJ Case Rep 2015; Oct 19 pii: bcr2015212639
• 4 de Courten B, Mousa A, Naderpoor N. et al. Vitamin D supplementation for the prevention of type 2 diabetes in overweight adults: study protocol for a randomized controlled trial. Trials 2015; 16: 335
• 5 Pham TM, Ekwaru JP, Loehr SA. et al. The relationship of serum 25-hydroxyvitamin D and insulin resistance among nondiabetic Canadians: A longitudinal analysis of participants of a preventive health program. PLoS One 2015; 10: e0141081
• 6 Alcubierre N, Valls J, Rubinat E. et al. Vitamin D deficiency Is associated with the presence and severity of diabetic retinopathy in type 2 diabetes mellitus. J Diabetes Res 2015; 2015: 374178
• 7 Dalan R, Liew H, Assam PN. et al. A randomised controlled trial evaluating the impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes mellitus: The DIMENSION trial. DiabVasc Dis Res 2016; 13: 192-200
• 8 Scragg R, Waayer D, Stewart AW et al. The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. J Steroid Biochem Mol Biol 2015 pii: S0960-0760(15)30070-4
• 9 Mpandzou G, Aït Ben Haddou E, Regragui W. et al. Vitamin D deficiency and its role in neurological conditions: A review. Neurol (Paris) 2016; 172: 109-122
• 10 Karras S, Rapti E, Matsoukas S et al. Vitamin D in fibromyalgia: a causative or confounding biological interplay? Nutrients 2016; 8: pii: E343
• 11 Holick MF. Vitamin D, deficiency in 2010: health benefits of vitamin D and sunlight: a D-bate. Nat Rev Endocrinol 2011; 7: 73-75
• 12 Ross AC, Manson JE, Abrams SA. et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96: 53-58
• 13 Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008; 87: 688-691
• 14 Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73: 288-294
• 15 Meunier C, Montérémal J, Faure P. et al. Four years of LC-MS/MS method for quantification of 25-hydroxyvitamin D (D2+D3) for clinical practice. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 989: 54-61
• 16 Higashi T, Goto A, Morohashi M. et al. Development and validation of a method for determination of plasma 25-hydroxyvitamin D3 3-sulfate using liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 969: 230-234
• 17 Zhang SW, Jian W, Sullivan S. et al. Development and validation of an LC-MS/MS based method for quantification of 25 hydroxyvitamin D2 and 25 hydroxyvitamin D3 in human serum and plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 961: 62-70
• 18 Plíšek J, Krčmová LK, Aufartová J. et al. New approach for the clinical monitoring of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 by ultrahigh performance liquid chromatography with MS/MS based on the standard reference material 972. J Sep Sci 2013; 36: 3702-3708
• 19 Baecher S, Leinenbach A, Wright JA. et al. Simultaneous quantification of four vitamin D metabolites in human serum using high performance liquid chromatography tandem mass spectrometry for vitamin D profiling. Clin Bio chem 2012; 45: 1491-1496
• 20 Xie W, Chavez-Eng CM, Fang W. et al. Quantitative liquid chromatographic and tandem mass spectrometric determination of vitamin D3 in human serum with derivatization: a comparison of in-tube LLE, 96-well plate LLE and in-tip SPME. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1457-1466